Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-4849 in combination with other antineoplastic drugs for malignant solid tumors
NCT07028281Phase 2Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Jul 2025
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-4849 in malignant solid tumor, sponsored by Suzhou Suncadia Biopharmaceutical. Started Jul 2025; status: recruiting.
02
Drugs
SHR-4849
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT07028281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07028281.